Primary Aldosteronism In Hypertensive Patients in China

Last updated: October 22, 2020
Sponsor: Qifu Li
Overall Status: Completed

Phase

N/A

Condition

Circulation Disorders

Williams Syndrome

Stress

Treatment

N/A

Clinical Study ID

NCT03155139
PA-China 2017
  • Ages 18-80
  • All Genders

Study Summary

To investigate the prevalence of primary aldosteronism (PA) in Chinese patients with newly diagnosed hypertension.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Newly diagnosed hypertension(with a course less than six months);

  2. Drug negative, or voluntary to discontinue/change the anti-hypertensive medications;

  3. Aged between 18-80 year, gender is not limited;

  4. Voluntary to sign on the informed consent.

Exclusion

Exclusion Criteria:

  1. patients with severe cardiac, hepatic or renal dysfunction;

  2. suspicious or confirmed other types of secondary hypertension, including Cushing'ssyndrome, pheochromocytoma and renal artery stenosis.

Study Design

Total Participants: 3500
Study Start date:
June 03, 2017
Estimated Completion Date:
November 30, 2018

Study Description

This is a nationwide sampling study. To investigate the prevalence of primary aldosteronism (PA) in Chinese patients with hypertension, we will conduct a case detection of PA in Chinese hypertensive patients from 10 centers of China (including Beijing, Chongqing, Shanghai, Guangzhou, et al.); furthermore, a case confirmation of PA (captopril challenge test and saline infusion test) will be performed if the result of case detection is positive. This study will be completed in two years.

Connect with a study center

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing 400016
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.